Table 3.
PCR-corrected efficacy rates of ACT and non-ACT after 28 and 42 days of follow-up from studies included in the review.
| Authors_Year | ACT tested | Type of analysis | 28-day ACPR (%) | 42-day ACPR (%) |
|---|---|---|---|---|
| Djimdé et al. (2008) | AS + AQ | PP | 99.1 | – |
| AS + SP | PP | 100.0 | – | |
| Happi et al. (2009)a | AL | ITT | 95.6 | 82.2 |
| Karema et al. (2010)a | AS + CPG-DDS | ITT | 70.5–73.3 | – |
| AQ + SP | ITT | 38.1–87.8 | – | |
| Somé et al. (2010)a | AL | ITT | – | 68.8 |
| DHA + PPQ | ITT | – | 89.1–92.4 | |
| AQ + SP | ITT | – | 88.2 | |
| Baliraine and Rosenthal (2011)a | AL | ITT | 89.1 | – |
| AS + AQ | ITT | 79.3 | – | |
| AQ + SP | ITT | 71.1 | – | |
| Gadalla et al. (2011) | AL | PP | 95.0 | 95.0 |
| Ngasala et al. (2011a) | AL | ITT | 98.2–98.8 | 95.8–98.1 |
| Ngasala et al. (2011b) | AL | ITT | 95.1 | 93.0 |
| Kamugisha et al. (2012) | AL | PP | 96.0 | – |
| Gadalla et al. (2013) | AS + SP | PP | 90.5 | – |
| ITT | 85.3 | – | ||
| Kiaco et al. (2015) | AL | PP | 91.3 | – |
| Warsame et al. (2015) | AS + SP | PP | 77.8–99.0 | – |
| ITT | 79.3–99.0 | |||
| Otienoburu et al. (2016) | AL | – | – | – |
| AS + AQ | – | – | – | |
| Sondo et al. (2016)a | AL | PP | 77.8 | – |
| AS + AQ | PP | 84.1 | – | |
| Yeka et al. (2016) | AS + AQ | ITT | 70.7 | – |
| AL | ITT | 54.3 | – | |
| Plucinski et al. (2017) | AL | PP | 86.5–96.1 | – |
| AS + AQ | PP | 99.9–100.0 | – | |
| DHA + PPQ | PP | 98.8–100.0 | 98.8–100.0 | |
| AL | ITT | 88.1–96.3 | – | |
| AS + AQ | ITT | 99.9–100.0 | – | |
| DHA + PPQ | ITT | 98.8–100.0 | 98.8–100.0 | |
| Warsame et al. (2017) | AL | PP | 97.6–100.0 | – |
| ITT | 91.1–100b | |||
| AS + SP | PP | 87.7 | – | |
| ITT | 78.8b | |||
| Baraka et al. (2018)a | AL | PP | NE | NE |
| AS + AQ | PP | NE | NE | |
| Davlantes et al. (2018) | AL | PP | 95.5–96.4 | – |
| AS + AQ | PP | 93.0–100.0 | – | |
| DHA + PPQ | PP | – | 100.0 | |
| AL | ITT | 95.5–96.5 | – | |
| AS + AQ | ITT | 93.3–100.0 | – | |
| DHA + PPQ | ITT | 100.0 | 100.0 | |
| Kakolwa et al. (2018) | AS + AQ | PP | NE | – |
| AL | PP | NE | – | |
| DHA + PPQ | PP | – | NE | |
| Smith et al. (2018) | AS + AQ | PP | 100.0 | – |
| AL | PP | 100.0 | – | |
| DHA + PPQ | PP | – | 100.0 | |
| AS + AQ | ITT | 100.0 | – | |
| AL | ITT | 100.0 | – | |
| DHA + PPQ | ITT | – | 100.0 | |
| Saha et al. (2012) | AS + SP | PP | – | 90.6 |
| AL | PP | – | 95.6 | |
| AS + MQ | PP | – | 100 | |
| Mishra et al. (2012) | AS + SP | ITT | 98.8 | – |
| Ganguly et al. (2013) | AS + SP | PP | – | 97.0 |
| Srivastava et al. (2013) | AS + SP | ITT | 100.0 | – |
| Mishra et al. (2014) | AS + SP | ITT | – | 59.5–82.7 |
| Mishra et al. (2017) | AS + SP | PP | 98.7–100.0 | – |
| Das et al. (2018) | AS + SP | _ | _ | _ |
ACT: Artemisinin-based combination therapy; ACPR: adequate clinical and parasitological response; AL: artemether + lumefantrine; AS + AQ: artesunate + amodiaquine; AS + CPG-DDS: Artesunate + Chlorproguanil-Dapsone; AS + MQ: artesunate + mefloquine; AS + SP: artesunate + sulfadoxine-pyrimethamine; DHA + PPQ: dihydroartemisinin + piperaquine; PP: per protocol; ITT: Intention-to-treat; NE: Non extractible.
a
These studies were secondary analysis of previously published trials. Thus information was obtained from the primary studies.
b
Compute based on data presented in the study.